Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial

被引：0
|
作者：
Jianhong Zhu
Wenxia Zhao
Dan Liang
Guocheng Li
Kaifeng Qiu
Junyan Wu
Jianfang Li
机构：
[1] Sun Yat-Sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation
[2] Sun Yat-sen University,Department of Pharmacy
[3] Sun-Yat-Sen Memorial Hospital,undefined
[4] Sun Yat-sen University,undefined
来源：
International Journal of Clinical Oncology | 2018年 / 23卷
关键词：
Anti-EGFR MAbs; Fatigue; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 399
页数：10
相关论文
共 50 条
  • [1] Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial
    Zhu, Jianhong
    Zhao, Wenxia
    Liang, Dan
    Li, Guocheng
    Qiu, Kaifeng
    Wu, Junyan
    Li, Jianfang
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (02) : 389 - 399
  • [2] ANTI-EGFR MONOCLONAL ANTIBODIES AND RISK OF SEVERE HAEMATOLOGICAL ADVERSE EVENTS IN CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Miroddi, M.
    Pellegrino, P.
    Sterrantino, C.
    Caridi, L.
    Rollo, A.
    Perrotta, C.
    Calapai, G.
    Radice, S.
    Clementi, E.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E83 - E83
  • [3] ANTI-EGFR MONOCLONAL ANTIBODIES INCREASE THE RISK OF PULMONARY EMBOLISM IN CANCER PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS
    Miroddi, M.
    Sterrantino, C.
    Conti, V.
    Rollo, A.
    Calapai, G.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E83 - E83
  • [4] Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)
    Miroddi, Marco
    Sterrantino, Carmelo
    Simmonds, Mark
    Caridi, Luigi
    Calapai, Gioacchino
    Phillips, Robert S.
    Stewart, Lesley A.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (10) : 2370 - 2380
  • [5] Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis
    Rizzo, Alessandro
    Frega, Giorgio
    Ricci, Angela Dalia
    Palloni, Andrea
    Abbati, Francesca
    De Lorenzo, Stefania
    Deserti, Marzia
    Tavolari, Simona
    Brandi, Giovanni
    IN VIVO, 2020, 34 (02): : 479 - 488
  • [6] ANTI-EGFR MONOCLONAL ANTIBODIES INCREASE THE RISK OF SEVERE GASTROINTESTINAL ADVERSE EVENTS IN CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Sterrantino, C.
    Miroddi, M.
    Conti, V.
    Caridi, L.
    Venegoni, M.
    Calapai, G.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E83 - E84
  • [7] Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials
    Li, Jing
    Xie, Jing
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (08) : 718 - 727
  • [8] Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis
    Funakoshi, Tomohiro
    Suzuki, Maya
    Tamura, Kazuo
    CANCER TREATMENT REVIEWS, 2014, 40 (10) : 1221 - 1229
  • [9] Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
    Li, Jing
    Yan, Hengxiu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 571 - 583
  • [10] Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
    Jing Li
    Hengxiu Yan
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 571 - 583
12345